#pharmaceutical-ai News & Analysis

8 articles tagged with #pharmaceutical-ai. AI-curated summaries with sentiment analysis and key takeaways from 50+ sources.

8 articles

AIBullishCrypto Briefing · Jun 217/10

🧠

Absci Corporation progresses ABS-201 into human trials, bolstering AI-driven drug discovery

Absci Corporation has advanced its AI-driven drug candidate ABS-201 into human clinical trials, marking a significant milestone in the application of artificial intelligence to pharmaceutical development. This progression demonstrates that AI-accelerated drug discovery can compress traditional development timelines, potentially reshaping how biotech companies approach drug development and reducing time-to-market for new therapies.

AIBullishBlockonomi · Apr 177/10

🧠

OpenAI Unveils GPT-Rosalind: New AI Model Targeting Pharmaceutical Research Acceleration

OpenAI has launched GPT-Rosalind, an AI model designed to accelerate pharmaceutical drug discovery, partnering with major life sciences companies including Amgen, Moderna, and Thermo Fisher. The model represents a significant application of advanced AI technology beyond traditional software domains, with potential to compress drug development timelines and reduce research costs.

🏢 OpenAI

AINeutralarXiv – CS AI · Jun 46/10

🧠

Breaking Bad Molecules: Are MLLMs Ready for Structure-Level Molecular Detoxification?

Researchers introduce ToxiMol, the first benchmark dataset and evaluation framework for assessing Multimodal Large Language Models (MLLMs) on molecular toxicity repair—the task of generating structurally valid alternatives to toxic compounds. Testing 43 mainstream MLLMs reveals current models show promise in toxicity understanding and constraint adherence but face significant challenges in this specialized pharmaceutical application.

AIBullisharXiv – CS AI · Jun 26/10

🧠

Probe Before You Edit: Probing-Guided Molecular Optimization for LLM Agents in Structure-Based Drug Design

Researchers introduce PROBE, a novel optimization framework that enables LLM agents to design drugs more effectively by probing molecular structures before making edits. The method addresses a critical failure in current drug-design pipelines: agents often sacrifice druggability when optimizing for binding affinity. PROBE achieves state-of-the-art results on standard benchmarks by mimicking how medicinal chemists strategically explore chemical modifications.

AIBullisharXiv – CS AI · Jun 26/10

🧠

When Single Answer Is Not Enough: Rethinking Single-Step Retrosynthesis Benchmarks for LLMs

Researchers propose a new benchmarking framework for evaluating large language models in retrosynthesis planning, introducing ChemCensor—a metric prioritizing chemical plausibility over exact-match accuracy—and CREED, a dataset of millions of validated reaction records that improves model performance beyond existing LLM baselines.

AIBullisharXiv – CS AI · May 76/10

🧠

Curated AI beats frontier LLMs at pharma asset discovery

Gosset, a curated AI platform for pharmaceutical asset discovery, outperforms leading frontier LLMs (Claude, GPT-5.5, Gemini, Perplexity) by 3.2x on drug discovery queries, achieving perfect precision and complete recall on niche oncology and immunology targets. The research demonstrates that specialized, annotated databases significantly outperform general-purpose models with web search for domain-specific tasks.

🏢 Perplexity🧠 GPT-5🧠 Claude

AIBullishcrypto.news · Apr 146/10

🧠

Senhwa Biosciences inks up to $16M funding deal with GEM to boost AI drug discovery

Taiwanese biopharmaceutical company Senhwa Biosciences has secured up to $16 million in funding from GEM through a memorandum of understanding to accelerate AI-driven drug discovery. This partnership represents growing institutional investment in combining artificial intelligence with pharmaceutical development to expedite clinical-stage research.

AIBullisharXiv – CS AI · Mar 36/106

🧠

GlassMol: Interpretable Molecular Property Prediction with Concept Bottleneck Models

Researchers introduce GlassMol, a new interpretable AI model for molecular property prediction that addresses the black-box problem in drug discovery. The model uses Concept Bottleneck Models with automated concept curation and LLM-guided selection, achieving performance that matches or exceeds traditional black-box models across thirteen benchmarks.